Gossamer Bio, Inc. (GOSS) stock
Close on Nov 12, 2026Market cap $68.75MP/E –Yield –
Gossamer Bio, Inc. grew revenue 78.0% to $78.42M over the twelve months to Sep 30, 2026. Free cash flow was -$156.04M. At the latest close the market valued the company at $68.75M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $68.75M
- P/E ratio
- –
- Price to sales
- 0.88
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -226.97%
Fundamentals
- Revenue
- $78.42M
- Net income
- -$125.07M
- EPS, diluted
- -$46.05
- Free cash flow
- -$156.04M
- Book value per share
- -$18.80
- Diluted shares
- 7M
Trading
- Next earnings
- Mar 16, 2027 (estimated, after the close)
- Previous close
- $11.69
- Open
- $11.27
- Day's range
- $10.60 – $12.15
- Volume
- 188,995
- Average volume (20 days)
- 176,342
- Beta (5 years)
- 1.58
- 52-week range
- $8.29 – $309.60
- RSI (14 days)
- 57.1
- Volatility (1 year)
- 140.9%
- Relative volume
- 0.58×
- WACC
- 12.8%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GOSS | S&P 500 | Difference | GOSS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.1% | -2.7% | +23.8 pts | ||
| 3 months | -20.9% | -1.7% | −19.1 pts | ||
| Year to date | -95.5% | +11.9% | −107.4 pts | ||
| 1 year | -94.8% | +12.0% | −106.8 pts | ||
| 3 years | -73.2% | +78.2% | −151.4 pts | -35.5% | +21.2% |
| 5 years | -98.8% | +73.2% | −172.1 pts | -59.0% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Gossamer Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Results
- Results
About Gossamer Bio
Pharmaceutical Preparations
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic treatments for pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company's primary investigational product candidate is seralutinib, an inhaled kinase inhibitor targeting PDGFR, CSF1R, and c-KIT pathways designed to address the underlying cellular overgrowth in lung blood vessels. Additionally, the company holds an option agreement to develop RT234, an investigational inhaled dry-powder formulation intended for on-demand symptom management. Its target population comprises patients suffering from progressive pulmonary vascular and fibrotic lung diseases.
Company profile, executives and historyGossamer Bio stock: common questions
What is Gossamer Bio's stock price?
GOSS closed at $11.24 on Nov 12, 2026, down 3.85% on the day. Over the past 52 weeks it traded between $8.29 and $309.60.
What is Gossamer Bio's market cap?
Gossamer Bio was worth $68.75M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is GOSS's P/E ratio?
Gossamer Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$46.05), so it has no meaningful P/E ratio.
How much revenue does Gossamer Bio make?
Gossamer Bio reported revenue of $78.42M for the twelve months to Sep 30, 2026, up 78.0% from a year earlier.
Does Gossamer Bio pay a dividend?
No. Gossamer Bio has not paid a cash dividend over the last twelve months.
When does Gossamer Bio report earnings next?
Gossamer Bio is expected to report Q4 FY2026 results on Mar 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has GOSS stock performed over the past year?
Including dividends, GOSS returned -94.8% over the past year, against +12.0% for the S&P 500.
Who are Gossamer Bio's competitors?
Companies most similar to Gossamer Bio by business, industry and size include GYRE, CYTK, KROS, VSTM, ROIV.
See a number that looks wrong?